1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Jian Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Regorafenib Combined With Envafolimab to Physician's Choice in Patients With Metastatic Gastrointestinal Stromal Tumors Harboring KIT Exon 17 Mutations Refractory to Standard Treatment physician-selected treatment, Regorafenib + Envafolimab - GIST - Gastrointestinal Stromal Tumor, KIT Gene Mutation | Phase 2 | Recruiting | Jian Li | 100 | 2025-07-14 | 2026-04-30 |
Gastrointestinal Stromal Tumors (1) · Piebaldism (1)
envafolimab (1) · regorafenib (1)
China (1)